Veeva Introduces Application for Clinical Research Centers to Simplify and Streamline Study Activities
PLEASANTON, CA - Oct. 11, 2018 - Veeva Systems (NYSE:VEEV) today introduced its first application specifically built for clinical research centers, Veeva Vault SiteDocs. The new solution will help sites more effectively manage regulatory documentation and trial information to speed clinical research. Now clinical research centers can reduce the administrative burden of executing studies by streamlining document and trial processes for site qualification, study activation, and investigator site file management.
“We’re pleased to partner with Veeva and have the opportunity to leverage an innovative solution that’s designed for how sites work,” said Dr. Jeff Kingsley, founder and CEO, IACT Health. “Veeva Vault SiteDocs gives greater visibility into regulatory document status and makes it easier for the clinical research community to conduct high-quality, compliant clinical trials.”
Veeva Vault SiteDocs provides sites a single application for managing trial documents and processes to speed study activation. With continuous visibility into document quality, completeness, and accuracy, Vault SiteDocs gives clinical research centers a full view into study progress for improved compliance and inspection-readiness.
“We’re honored to support the important work of clinical research centers and partner with organizations such as IACT Health and Penn Medicine,” said Jennifer Goldsmith, senior vice president of Veeva Vault. “Veeva Vault SiteDocs aims to simplify study execution so research staff can focus on the science and accelerate their research efforts.”
Veeva Vault SiteDocs is available today for clinical research centers. Join Veeva at the upcoming 2018 Global Site Solutions Summit, Oct. 12-14, to learn more and see a demonstration of Veeva Vault SiteDocs in booth #501.
Additional Information
For more information, visit: veeva.com/VaultSiteDocs
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 650 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
###
Contacts:
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Lisa Barbadora
Veeva Systems
610-420-3413
pr@veeva.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
